Dr. Sanket Mehta

Dr. Sanket Mehta

Book an Appointment
+91 8268880185
Highest level of ethical standards &
professional excellence in oncological care.
SCROLL DOWN

A Vision of Excellence

About Dr. Mehta

Leading the vanguard of Cytoreductive Surgery (CRS) and HIPEC in the country, Dr. Sanket Mehta focuses on the quality of care with surgical proficiency and patient centric treatment. The highest quality services are an amalgamation of complex procedures, medical expertise, a humane touch and a vision of excellence.

A Vision
of Excellence

Leading the vanguard of Cytoreductive Surgery (CRS) and HIPEC in the country, Dr. Sanket Mehta focuses on the quality of care with surgical proficiency and patient centric treatment. The highest quality services are an amalgamation of complex procedures, medical expertise, a humane touch and a vision of excellence.

About Dr. Mehta

Pioneer of

CRS & HIPEC

Surgeries

1000+

Years of experience

11+

Modern Oncological Treatment of International Standards

READ MORE

Highest Standards of Patient Care & Safety

Highest Standards of Patient Care & Safety

With 11+ years of medical experience Dr. Mehta offers world-class diagnostic, therapeutic and rehabilitative care of the highest standards.
our approach

Hospital Affiliations

Specialty Surgical Oncology Hospital and Research Centre

Saifee Hospital

Sir H N Reliance Foundation Hospital

Breach Candy Hospital

Hear It From
Our Patients

BOOK AN APPOINTMENT
[sp_testimonial id="268" ]

Medreads

READ MORE
September 2, 2021
Gastrointestinal & Colon Cancers
September 1, 2021
Peritoneal Mesothelioma
August 31, 2021
Ovarian Cancer
August 30, 2021
Rectum Cancer
Gastrointestinal & Colon Cancers
2 September, 2021
Peritoneal Mesothelioma
1 September, 2021
Ovarian Cancer
31 August, 2021
Rectum Cancer
30 August, 2021
READ MORE

Our Publications

READ MORE
3 July, 2021
Human papillomavirus infection: Is it associated with epithelial ovarian cancer?
VIEW FULL ARTICLE
21 January, 2021
Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer
VIEW FULL ARTICLE
1 January, 2021
Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications
VIEW FULL ARTICLE
18 November, 2020
Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study
VIEW FULL ARTICLE
29 August, 2020
Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
VIEW FULL ARTICLE
READ MORE